J. Brunetta

发表

Immunologic Effectiveness of Maraviroc- and Raltegravir-Containing Regimens (R+M+) versus Raltegravir-Based Regimens That Do Not Include Maraviroc (R+M−)

C. Kovacs, T. Antoniou, M. Loutfy, 2012, Journal of the International Association of Physicians in AIDS Care.

Survey of healthcare providers' practices and opinions regarding bacterial STI testing among gay, bisexual and other men who have sex with men.

A. Burchell, Darrell H S Tan, C. Logie, 2020, Sexually transmitted diseases.

Health Impacts and Characteristics of Deprescribing Interventions in Older Adults: Protocol for a Systematic Review and Meta-analysis

A. Burchell, Darrell H S Tan, C. Logie, 2019, JMIR research protocols.

Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial.

J. Baeten, D. Podzamczer, M. Das, 2021, The lancet. HIV.

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study.

J. van Lunzen, M. Cavassini, C. Orkin, 2016, The Lancet. Infectious diseases.

Four-Year Follow-Up of Polyalkylimide Gel Use for the Treatment of HIV-Associated Lipoatrophy

C. Kovacs, T. Antoniou, M. Loutfy, 2011, HIV clinical trials.

Long-term efficacy and safety of polyalkylimide gel for the treatment of HIV-associated lipoatrophy

C. Kovacs, T. Antoniou, M. Loutfy, 2009, AIDS care.

Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results

K. Tashima, P. Sax, M. Das, 2016, Journal of acquired immune deficiency syndromes.

Community-associated methicillin-resistant Staphylococcus aureus infections in men who have sex with men: A case series.

C. Kovacs, M. Mulvey, T. Antoniou, 2007, The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale.

Cross-sectional comparison of age- and gender-related comorbidities in people living with HIV in Canada.

Réjean Thomas, J. Baril, A. Wong, 2022, Medicine.

Prosecution of non-disclosure of HIV status: Potential impact on HIV testing and transmission among HIV-negative men who have sex with men

R. Kaul, M. Loutfy, T. Myers, 2018, PloS one.

HIV & Hepatitis in the Americas 28–30 April 2016, Mexico City, Mexico

N. Volkow, K. Tashima, D. Podzamczer, 2016, Journal of the International AIDS Society.

Assessment of antiretroviral third agent virologic durability after initiation of first antiretroviral regimen

C. Kovacs, M. Loutfy, B. Varriano, 2019, International journal of STD & AIDS.

Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B–Coinfected Adults

J. Gallant, M. Das, S. Oka, 2016, Journal of Acquired Immune Deficiency Syndromes.

Effect of valaciclovir on CD4 count decline in untreated HIV: an international randomized controlled trial

S. Trottier, A. Winston, B. Conway, 2018, The Journal of antimicrobial chemotherapy.

Herpes simplex virus type 2 coinfection does not accelerate CD4 count decline in untreated HIV infection.

R. Kaul, C. Kovacs, J. Raboud, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

HPV genotyping and risk factors for anal high-risk HPV infection in men who have sex with men from Toronto, Canada

R. Kaul, M. Loutfy, S. Huibner, 2021, Scientific Reports.

Gemini: A Noninferiority Study of Saquinavir/Ritonavir Versus Lopinavir/Ritonavir as Initial HIV-1 Therapy in Adults

D. Ward, K. Ruxrungtham, S. Walmsley, 2009, Journal of acquired immune deficiency syndromes.

1585. Efficacy and safety of long-acting subcutaneous lenacapavir in heavily treatment-experienced people with multi-drug resistant HIV: Week 52 results

J. Baeten, H. Dvory‐Sobol, J. Molina, 2022, Open Forum Infectious Diseases.

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK

Samit R. Joshi, Charlene A Flash, Thomas Lengauer, 2014 .

Impact of Baseline NNRTI Resistance in Antiretroviral-naÃ¯ve Patients with HIV in A Large Urban Clinic

C. Kovacs, M. Loutfy, B. Varriano, 2018 .

Asymptomatic neurocognitive impairment is a risk for symptomatic decline in a large HIV Canadian cohort study.

C. Kovacs, T. Marcotte, M. Gill, 2020, AIDS (London).

Prevalence of community-associated methicillin-resistant Staphylococcus aureus colonization in men who have sex with men

C. Kovacs, M. Mulvey, T. Antoniou, 2009, International journal of STD & AIDS.

Prevalence of Sexually Transmitted Viral and Bacterial Infections in HIV-Positive and HIV-Negative Men Who Have Sex with Men in Toronto

R. Kaul, M. Loutfy, S. Huibner, 2016, PloS one.

Community-Directed Bacterial Sexually Transmitted Infection Testing Interventions Among Men Who Have Sex With Men: Protocol for an E-Delphi Study in Toronto, Canada (Preprint)

A. Burchell, C. Logie, M. Gilbert, 2019 .

Time to Viremia for Patients Taking their First Antiretroviral Regimen and the Subsequent Resistance Profiles

C. Kovacs, M. Loutfy, W. Barrie, 2016, HIV clinical trials.

Changes in renal and metabolic indices after switching from tenofovir disoproxil fumarate– to tenofovir alafenamide–containing ART among individuals with HIV in Canada: A retrospective study

C. Kovacs, Meenakshi Gupta, M. Loutfy, 2021, International journal of STD & AIDS.

Evaluation of brief screening tools for neurocognitive impairment in HIV/AIDS: a systematic review of the literature

T. Marcotte, M. Gill, S. Rourke, 2013, AIDS.

Pharmacokinetics of Raltegravir in the Semen of HIV-Infectedmen

T. Antoniou, M. Loutfy, C. L. la Porte, 2014, Antiviral therapy.

Pharmacokinetics of maraviroc, raltegravir, darunavir, and etravirine in the semen of HIV-infected men.

C. Kovacs, T. Antoniou, M. Loutfy, 2013, Journal of acquired immune deficiency syndromes.

Effect of raltegravir intensification on HIV proviral DNA in the blood and gut mucosa of men on long-term therapy: a randomized controlled trial

R. Kaul, M. Ostrowski, C. Kovacs, 2012, AIDS.

Patient-Reported Outcomes After a Switch to a Single-Tablet Regimen of Rilpivirine, Emtricitabine, and Tenofovir DF in HIV-1-Positive, Virologically Suppressed Individuals: Additional Findings From a Randomized, Open-Label, 48-Week Trial

M. Johnson, A. Antinori, R. Ebrahimi, 2015, The Patient - Patient-Centered Outcomes Research.

Health Impacts and Characteristics of Deprescribing Interventions in Older Adults: Protocol for a Systematic Review and Meta-analysis

A. Burchell, C. Logie, D. Gesink, 2019, JMIR research protocols.

Immunologic Effectiveness of Maraviroc- and Raltegravir-Containing Regimens (R+M+) versus Raltegravir-Based Regimens That Do Not Include Maraviroc (R+M−)

C. Kovacs, T. Antoniou, M. Loutfy, 2012, Journal of the International Association of Physicians in AIDS Care.

Herpes simplex virus type 2 coinfection does not accelerate CD4 count decline in untreated HIV infection.

R. Kaul, C. Kovacs, J. Raboud, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.